Three Oncology Drug Candidates Show Clinical Success
Biopharmaceutical companies report positive clinical trial results for lung cancer, sarcoma, and melanoma treatments.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Should the development of expensive, specialized cancer treatments be a top national health priority?
Three drug makers announced promising results from recent clinical trials for new oncology therapies. These treatments target non-small cell lung cancer, relapsed osteosarcoma, and high PRAME expression in melanoma patients.
Why it matters
These results provide potential new therapeutic options for patients battling aggressive cancers where existing chemotherapy treatments have limited effectiveness. The data marks a notable step forward in targeting specific proteins and cell surface markers to improve survival outcomes.
Patients treated with izalontamab brengitecan showed a median progression-free survival of 11.1 months, while the Ris-Rez treatment achieved 5.5 months of median survival compared to 1.4 months for chemotherapy. IMA402 demonstrated a 32% response rate.
The players
Bristol Myers Squibb
This global biopharmaceutical company focuses on discovering and developing innovative medicines for serious diseases including cancer.
GSK
Formerly GlaxoSmithKline, this multinational pharmaceutical company is actively involved in global sarcoma clinical research.
Immatics
This clinical-stage biopharmaceutical company specializes in the development of T cell receptor-based immunotherapies for cancer.
SystImmune
This biotechnology company focuses on the development of multi-specific antibodies and antibody-drug conjugates for oncology.
Hansoh
This Chinese pharmaceutical firm is preparing to file for regulatory approval for new cancer treatments based on recent clinical findings.
The details
Iza-bren, which targets both EGFR and HER3 proteins, nearly doubled progression-free survival compared to standard chemotherapy in EGFR-mutated non-small cell lung cancer. Meanwhile, the IMA402 candidate, which recruits T cells to recognize PRAME fragments, showed a 91% one-year survival rate among patients in the recommended dose range.
Timeline
Clinical trial results were reported in October 2026.
The Big Picture
This development follows the research patterns established by the PANKU-Lung01 clinical trial. It reflects a paradigm shift toward multi-target antibody-drug conjugates and cell-surface directed immunotherapies that replace older, less specific chemotherapy regimens.
These findings could expand future treatment options for patients with specific genetic mutations or protein expressions that do not respond well to standard chemotherapy. Patients should consult their oncologists to determine if they might be eligible for future clinical trials.
The takeaway
The successful trial data for these candidates highlights the potential for targeted biologics to outperform traditional chemotherapy in specific oncology patient populations. Continued monitoring of phase 3 trials will be essential for confirming the long-term viability of these treatments.
What happens next
Hansoh plans to initiate the regulatory filing process for its drug candidate in China following these trial outcomes.
Further reading
Learn more about the latest developments in cancer research in our Cancer section.
Source note: This article includes information reported by BioPharm International.
Live Poll
Should the development of expensive, specialized cancer treatments be a top national health priority?
